021-51111890
购物车（0）
sales@molnova.cn
PMX 53 acetate(219639-75-5 free base)
CAS No. 852629-88-0
PMX 53 acetate(219639-75-5 free base) ( —— )
产品货号. M37923 CAS No. 852629-88-0
PMX-53 is a potent and orally active CD88 (C5aR) antagonist (IC50: 20 nM) and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also an agonist of Mas-related gene 2 (MrgX2).
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥1460 | 有现货 |
|
| 5MG | ￥2083 | 有现货 |
|
| 10MG | ￥3085 | 有现货 |
|
| 25MG | ￥4629 | 有现货 |
|
| 50MG | ￥6381 | 有现货 |
|
| 100MG | ￥8339 | 有现货 |
|
| 200MG | ￥11322 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称PMX 53 acetate(219639-75-5 free base)
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述PMX-53 is a potent and orally active CD88 (C5aR) antagonist (IC50: 20 nM) and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also an agonist of Mas-related gene 2 (MrgX2).
-
产品描述PMX-53 is a potent and orally active CD88 (C5aR) antagonist (IC50: 20 nM) and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also an agonist of Mas-related gene 2 (MrgX2).
-
体外实验——
-
体内实验——
-
同义词——
-
通路Immunology/Inflammation
-
靶点Complement System
-
受体Complement System
-
研究领域——
-
适应症——
化学信息
-
CAS Number852629-88-0
-
分子量956.16
-
分子式C49H69N11O9
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESN=C(N)NCCC[C@@H]1NC([C@H](CC2=CNC3=C2C=CC=C3)NC([C@@H](CC4CCCCC4)NC([C@H]5N(C([C@H](CCCNC1=O)NC([C@H](CC6=CC=CC=C6)NC(C)=O)=O)=O)CCC5)=O)=O)=O.CC(O)=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
产品手册
关联产品
-
C3a Receptor Agonist
C3a receptor agonist 1 (compound benzoacetamide) 是一种有效的 C3a receptor 激动剂。C3a receptor agonist 1 具有研究急性炎症的潜力。
-
C3a 70-77 2TFA(63555...
C3a 70-77 2TFA 是对应于 C3a 的 COOH 末端的八肽。
-
Vesencumab
Vesencumab (MNRP-1685A) 是针对 neuropilin-1 (NRP-1) 的 IG1 抗体。Vesencumab 与 NRP-1 结合并阻止 NRP-1 与 VEGFR-2 偶联。Vesencumab 具有抗血管生成和抗肿瘤活性。Vesencumab可用于转移性实体瘤的研究，包括卵巢癌。
